相关实验视频
Updated: Feb 22, 2026
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
5.4K
向PFKFB3-依赖性内皮质-介质酶转换的黄素减轻了多克索鲁比诱导的心脏毒性
Xinyi Zhong1, Yu Xia1, Nan Li1
1School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
概括
卢泰林通过向PFKFB3来抑制内皮-介质细胞转换 (EndMT) 来预防多克索鲁比诱导的心脏毒性 (DIC). 这种天然化合物可以作为对DIC有益的辅助疗法,而不会影响化疗的疗效.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 多克索鲁比 (DOX) 化疗受到心脏毒性 (DIC) 的限制.
- 内皮介质转换 (EndMT) 是一种有助于DIC的拟议机制.
- 鉴定对DIC的保护剂具有临床意义.
研究的目的:
- 研究黄素对DOX诱导心脏毒性 (DIC) 的保护作用.
- 阐明黄素在DIC中的作用的潜在分子机制.
- 评估黄素对EndMT的影响及其与PFKFB的相互作用3.
主要方法:
- 在DIC小鼠模型中评估心脏功能和心肌损伤生物标志物.
- 肌肉学分析心肌结构和纤维化.
- 单核RNA测序 (snRNA-seq) 用于识别关键的分子标.
- 分子对接和动力学模拟以研究氨酸-PFKFB3结合.
- 使用人类静脉内皮细胞 (HUVEC) 进行体外研究,以评估内皮功能和PFKFB3通路调节.
主要成果:
- 在DIC小鼠中,素治疗改善了心脏功能,并减少了心肌损伤标志物.
- 组织学表明,黄素可以缓解结构损伤和纤维化.
- snRNA-seq确定了PFKFB3作为EndMT的一个关键媒介.
- 通过向PFKFB3-介导的EndMT通路,素抑制了DOX诱导的内皮功能障碍.
- 素没有影响DOX的抗癌疗效.
结论:
- 素通过向PFKFB3和抑制EndMT. 改善DOX诱导的心脏毒性 (DIC).
- 卢铁显示出作为减轻DIC的辅助疗法的潜力.
- 需要对DIC预防的黄素进行进一步的研究.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
30
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
30
02:38Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K